Ankylosing spondylitis (AS), characterized by inflammatory back pain and sacroiliitis on radiography, was traditionally considered a condition predominant in men. Since the introduction of the 2009 Assessment in Spondyloarthritis international Society classification criteria aiming to facilitate earlier classification of cases without radiographic sacroiliitis, more women have been classified as having axial spondyloarthritis (axSpA). The prevalence of men/women with AS, which was 3:1 in the 1990s, is now equal in newer cohorts, particularly for nonradiographic (nr-) axSpA. Differences in the manifestations of axSpA between men and women have been increasingly recognized in the last decade. Studies have reported that women have more peripheral disease and higher pain, fatigue, and disease activity, whereas men have higher inflammatory markers and structural damage on radiography.

In this issue of The Journal of Rheumatology, Mease, et al report the sex differences in axSpA using real-world data from the Corrona Registry. The Corrona Psoriatic Arthritis and Spondyloarthritis (PsA/SpA) Registry is a large prospective observational cohort started in 2013 from 58 practices across 30 states in the United States. In their study, 498 patients with rheumatologist-diagnosed axSpA (without concurrent diagnosis of PsA) with baseline data for sex were included. Of these, 191 (38.4%) were women. There was a long delay in diagnosis of over 7 years in patients. In contrast to previous studies that cited a longer delay in diagnosis among women, there were no differences in diagnosis delay comparing men and women; this is possibly related to less emphasis on radiographic sacroilitis in diagnosis in the last decade. Women had more peripheral musculoskeletal manifestations, including higher tender/swollen joint counts and enthesitis count, and were more likely to have used prior conventional synthetic disease-modifying antirheumatic drugs and prednisolone. In addition, women had higher disease activity, poorer physical function, and worse physician global assessment compared to men. These differences between men and women were more prominent among patients with nr-axSpA than AS. Women had greater work productivity and activity impairment and were less likely to work full time than men. However, the higher rate of work productivity loss in women could be due to factors other than mere sex differences, including physical demand and the nature of the job. In addition, there may be social and cultural implications for men vs women in continuing or not continuing with full-time employment when facing a change in health condition.

There may be sex- or gender-related factors that could explain the variation in the manifestations between men and women with axSpA (Figure 1). Sex refers to a set of biological attributes related to chromosomes, genes and expression, hormonal function, and physique, whereas gender refers to the self-identity of men and women as shaped by psychological, social, and cultural influences.

Biological plausibility that may explain the sex-related differences in axSpA includes genetic, hormonal, and immunological aspects. The prevalence of HLA-B27, the most important genetic predisposition for axSpA, is higher among men with axSpA, and partially explains the higher radiographic damage and the spine and sacroiliac joint inflammation on magnetic resonance imaging among men than women. Further, other genes and single-nucleotide polymorphisms related to osteogenesis and ankylosis were found to be more prevalent in men than women. Hormonal differences may also contribute to the disparity in immune responses in men and women. Estrogen increases production of interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF)-α, whereas testosterone decreases TNF-α production but increases the production of antiinflammatory IL-10. Yet, conflicting results in studies in the role of
sex hormones in the development or progression of SpA warrant further investigation. From an immunological perspective, the frequency of peripheral blood IL-17A and Th17 cells, which are key players in the IL-23/IL-17 axis, was elevated in men but not in women with AS, compared to healthy controls.15 Again, this highlights the differences of activation status of the immune system that may underlie the sex-related differences in manifestations in axSpA.

A large part of the observed differences between men and women with axSpA may be related to gender. Consistent with previous studies, Mease, et al observed higher disease activity among women compared to men, most prominently in patient-reported outcomes (PROs) such as the Bath AS Disease Activity Index.6 There was no statistically significant difference seen with the AS Disease Activity Score, whereas C-reactive protein (CRP) was comparable between sexes in the study. Other PROs, including pain, fatigue, and Health Assessment Questionnaire–Disability Index, were scored higher among women compared to men. Interestingly, when patients were asked to rate their global assessment of disease activity, there was no statistically significant difference in scores between men and women. The exact reasons why men and women may experience life impact of axSpA differently are not entirely understood. Intuitively, these contrasts could be related to both the experience of symptoms and the reporting of these symptoms as they conform to gender roles. Social responsibilities vary between genders and so do expectations; therefore, there are also distinct ways that men and women may communicate and report those symptoms according to social norms. For example, women generally report higher pain intensity compared to men across both musculoskeletal and nonmusculoskeletal conditions.16 However, a major contributing factor in axSpA could be central pain sensitization, which refers to the amplification of neural signaling within the central nervous system that leads to pain hypersensitivity and the spread of pain to a broader area than the primary inflammatory sites. A similar concept is found in fibromyalgia (FM), which encompasses widespread pain, fatigue, sleep disturbance, and cognitive symptoms, and is a well-known contextual factor associated with overestimating measurements of disease activity.7 Using a body chart for painful locations in the body, it has been shown previously that women with axSpA have a more widespread pattern of painful locations, both along the axial and peripheral articular areas, than men.18 In the Corona Registry, Mease, et al collected data for FM according to physicians' judgment.6 The overall prevalence of FM (4.8%) was at the low end among those reported for SpA,19 yet there was a remarkable disparity in the prevalence of FM between sexes in the study (1% in men vs 10.5% in women). A higher prevalence of physician-reported depression among women compared to men was also observed (12.1% in men vs 25.7% in women), highlighting the psychological comorbidities that may influence PROs.

This study highlighted several important points. First, women with axSpA have more peripheral disease burden, the awareness of which should assist in earlier diagnosis. Second, disease activity measurements relying heavily on PROs are more vulnerable to contextual factors, such as comorbid FM and depression. Incorporating objective measurement of the pathophysiological inflammatory process is desirable. CRP could be an option, and the development of more objective biomarkers

---

**Figure 1.** Sex-related and gender-related factors explaining differences in manifestations between men and women with axial spondyloarthritis. F: female; M: male; PRO: patient-reported outcome; MRI: magnetic resonance imaging; QoL: quality of life.
is an important unmet need. Third, the life impact of SpA may be experienced differently for men and women. Awareness of the sex differences in disease impact is relevant to facilitate early diagnosis of axSpA, assessment of disease activity in axSpA, and personalization of treatment strategies for patients with distinct healthcare needs.

REFERENCES